Dermatologikum Hamburg GmbH — Clinical Trial Site

18 Registered trials

6 Currently recruiting

Organisation

Dermatologikum Hamburg GmbH

Location

Hamburg, Germany

Identifier

ORG-100044098

Address

Stephansplatz 5, Neustadt, 20354, Germany

Departments

Department for Clinical Research
Department of Dermatology
Dermatologie
Dermatologikum Hamburg
Dermatologikum Hamburg GmbH
Dermatology
N/A
NA
Not applicable

Clinical trials at this site (18)

Search interface

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis (ADAPTIVE) Pending

2024-520117-50-00 Atopic Dermatitis 4
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting

2024-519795-11-00 Atopic Dermatitis 4 2025-10-06
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
A Study to Assess the Long-Term Efficacy and Safety of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who participated in previou… Recruiting

2025-520771-59-00 Atopic Dermatitis 4 2026-02-03
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended

2024-515494-95-00 Moderate to Severe Atopic Dermatitis (AD) 4 2025-05-26
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended

2024-511260-84-00 Atopic Dermatitis 4 2024-09-03
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Ev… Ended

2024-514394-22-00 Actinic Keratosis 6 2022-10-24
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Dermatitis atopic 5 2024-06-26
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-S… Ended

2023-505558-16-00 Atopic Dermatitis 5 2023-10-24
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Atopic Dermatitis 5 2023-05-23
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25